- Conditions
- Advanced Urothelial Carcinoma, Oral Drug Administration, Open Label
- Interventions
- FX-909, Pembrolizumab (KEYTRUDA ®), KEYTRUDA ®( Pembrolizumab)
- Drug
- Lead sponsor
- Flare Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 12
- States / cities
- San Francisco, California • New Haven, Connecticut • Miami, Florida + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 673–696
of 1,234
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced Solid Tumor, Lymphoma
- Interventions
- GRC 54276, GRC 54276 + Pembrolizumab, GRC 54276 + Atezolizumab
- Drug
- Lead sponsor
- Glenmark Specialty S.A.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 2
- States / cities
- Huntersville, North Carolina • Milwaukee, Wisconsin
- Conditions
- Healthy
- Interventions
- NM8074, Placebo
- Drug
- Lead sponsor
- NovelMed Therapeutics
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Safety Issues
- Interventions
- EXT608, Placebo
- Drug · Other
- Lead sponsor
- Extend Biosciences Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Wound Heal, Peripheral Artery Disease, Ulcer, Leg, Ulcer Foot, Diabetic Foot Ulcer, Arterial Insufficiency
- Interventions
- Noxsano Bandage (Healthy Volunteers), Noxsano Bandage (Wound Care)
- Device
- Lead sponsor
- OhioHealth
- Other
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Solid Tumours
- Interventions
- BI 4060107
- Biological
- Lead sponsor
- AIMEDBIO
- Government
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Irving, Texas
- Conditions
- HEPATITIS B CHRONIC
- Interventions
- PBGENE-HBV
- Biological
- Lead sponsor
- Precision BioSciences, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma
- Interventions
- LY4584180, Rituximab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 21
- States / cities
- Scottsdale, Arizona • Duarte, California • Los Angeles, California + 16 more
- Conditions
- Netherton Syndrome
- Interventions
- BCX17725, Placebo
- Drug
- Lead sponsor
- BioCryst Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 5
- States / cities
- Palo Alto, California • San Diego, California • New Haven, Connecticut + 2 more
- Conditions
- Advanced Solid Tumor or Lymphoma
- Interventions
- BJ-005
- Biological
- Lead sponsor
- BJ Bioscience, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Port Saint Lucie, Florida + 3 more
- Conditions
- Metastatic NSCLC - Non-Small Cell Lung Cancer, Advanced Solid Tumor
- Interventions
- XTX501
- Drug
- Lead sponsor
- Xilio Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 3
- States / cities
- Canton, Ohio • Fort Worth, Texas • Fairfax, Virginia
- Conditions
- Select Advanced Solid Tumors
- Interventions
- CDR404
- Biological
- Lead sponsor
- CDR-Life AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Portland, Oregon • Philadelphia, Pennsylvania
- Conditions
- Respiratory Tract Infections
- Interventions
- PF-04287881, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Human Papillomavirus Infections
- Interventions
- Ad26.HPV16, Ad26.HPV18, MVA.HPV16/18, Placebo
- Biological
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 18 Years to 60 Years · Female only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 11
- States / cities
- Doral, Florida • Fort Myers, Florida • Miami, Florida + 8 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- AMG 570, AMG 570 Matching Placebo
- Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 3
- States / cities
- Evansville, Indiana • Overland Park, Kansas • Madison, Wisconsin
- Conditions
- Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Colorectal Neoplasms, Solid Carcinoma, Pancreatic Cancer
- Interventions
- DM002
- Drug
- Lead sponsor
- Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 4
- States / cities
- San Francisco, California • Huntersville, North Carolina • Oklahoma City, Oklahoma + 1 more
- Conditions
- HIV Infections
- Interventions
- Dolutegravir + Lamivudine FDC
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palm Springs, California + 12 more
- Conditions
- Neoplasms
- Interventions
- JNJ-88549968, Ruxolitinib, Momelotinib
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 18
- States / cities
- Goodyear, Arizona • Duarte, California • Aurora, Colorado + 15 more
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Mature B-cell Non-Hodgkin Lymphoma
- Interventions
- ATG-101
- Drug
- Lead sponsor
- Antengene Biologics Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 3
- States / cities
- San Francisco, California • St Louis, Missouri • Philadelphia, Pennsylvania
- Conditions
- Healthy Volunteers
- Interventions
- GFB-887, Placebo
- Drug
- Lead sponsor
- Goldfinch Bio, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation
- Interventions
- BAY2927088_formulation A, BAY2927088_formulation B_1, BAY2927088_formulation B_2, BAY2927088_formulation B_3
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 430 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2031
- U.S. locations
- 11
- States / cities
- Gilbert, Arizona • Duarte, California • Atlanta, Georgia + 7 more
- Conditions
- Herpes Zoster (HZ), Shingles, Infectious Disease
- Interventions
- JCXH-105, Active Control (Shingrix)
- Biological
- Lead sponsor
- Immorna Biotherapeutics, Inc.
- Industry
- Eligibility
- 50 Years to 69 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 3
- States / cities
- Hollywood, Florida • Tampa, Florida • Berlin, New Jersey
- Conditions
- Advanced Solid Tumors (Part A/B/C/D), Non-small Cell Lung Cancer (Part E), Melanoma (Part E), Squamous Cell Cancer of the Head and Neck (Part E), Triple Negative Breast Cancer (Part F), Adrenocortical Carcinoma (Part G), Mesothelioma (Part G), High-circulating Myeloid-derived Suppressor Cells (Part H)
- Interventions
- IPI-549 (eganelisib), Nivolumab
- Drug
- Lead sponsor
- Infinity Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 219 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 11
- States / cities
- San Diego, California • Santa Monica, California • Port Saint Lucie, Florida + 6 more
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Interventions
- GLB-001
- Drug
- Lead sponsor
- GluBio Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 8
- States / cities
- Duarte, California • Irvine, California • Kansas City, Kansas + 4 more